Thông tin thuốc gốc
Chỉ định và Liều dùng
Muscle relaxant in general anaesthesia
Adult: As suxamethonium Cl: 3-4 mg/kg. Max: 150 mg.
Child: As suxamethonium Cl: <1 yr Up to 5 mg/kg; ≥1 yr Up to 4 mg/kg. Max: 150 mg.

Muscle relaxant in general anaesthesia
Adult: As suxamethonium Cl: Single dose of 0.3-1.1 mg/kg by inj. Supplementary doses of 50-100% of the initial dose may be given at 5-10 min intervals. For prolonged procedures, 0.1-0.2% soln by infusion at 2.5-4 mg/min, adjusted as necessary. Max (repeated inj or continuous infusion): 500 mg/hr.
Child: As suxamethonium Cl: <1 yr 2 mg/kg; 1-12 yr 1 mg/kg.
Hướng dẫn pha thuốc
IV infusion: Suxamethonium Cl 1 g powd for inj or 20 mL of a soln containing 50 mg/mL may be added to 1,000 mL or 500 mL of diluent (e.g. dextrose 5%, dextrose 5% and NaCl 0.9%, NaCl 0.9%, or (1/6) M Na lactate inj) to provide a soln containing 1 mg/mL (0.1%) or 2 mg/mL (0.2%), respectively. Alternatively, suxamethonium Cl 500 mg powd for inj or 10 mL of a soln containing 50 mg/mL may be added to 500 mL or 250 mL of diluents to provide a soln containing 1 mg/mL (0.1%) or 2 mg/mL (0.2%), respectively.
Tương kỵ
Alkaline soln w/ pH exceeding 8.5 (e.g. barbiturates). Y-site: Thiopental, heparin.
Chống chỉ định
Genetically determined disorders of plasma pseudocholinesterase; personal or familial history of malignant hyperthermia, myopathies associated w/ elevated serum creatine kinase values, angle-closure glaucoma, penetrating eye injuries, raised intraocular pressure; neurological deficits involving acute major muscle wasting (upper and/or lower motor neuron lesions); extensive denervation of skeletal muscle because of disease or injury to the CNS, pre-existing hyperkalaemia. Patient recovering from major trauma, extensive or severe burns.
Thận trọng
Hypersensitivity to any neuromuscular blocker. Patient w/ reduced plasma cholinesterase activity, bone fractures, neuromuscular disorders, cardiac or resp disease, electrolyte imbalance, suspected cardiac glycoside toxicity. Childn. Pregnancy and lactation.
Tác dụng không mong muốn
Prolonged resp depression or apnoea, bradycardia, tachycardia, hypotension, HTN, raised intraocular pressure, hyperkalaemia, muscle fasciculation, excessive salivation, jaw rigidity, rash.
Potentially Fatal: Anaphylactic and anaphylactoid reactions, acute rhabdomyolysis w/ hyperkalaemia followed by ventricular dysrhythmias and cardiac arrest, malignant hyperthermia.
IM/IV/Parenteral: C
Chỉ số theo dõi
Monitor cardiac function and oxygenation during admin; temp, serum K and Ca, assisted ventilator status; neuromuscular function w/ peripheral nerve stimulator.
Quá liều
Symptoms: Apnoea, prolonged muscle paralysis, decreased resp reserve, low tidal vol. Management: Symptomatic and supportive treatment. Maintain airway and adequate ventilation until recovery of normal respiration is assured. Use of neostigmine to reverse a non-depolarising suxamethonium-induced block should be accompanied by appropriate doses of an anticholinergic agent (e.g. atropine).
Tương tác
Prolonged neuromuscular blocking effects w/ specific anticholinesterase agents (e.g. neostigmine), cytotoxic compd (e.g. cyclophosphamide), antiarrhythmics (e.g. quinidine), aminoglycosides, psychiatric drugs (e.g. chlorpromazine), Mg salts, anaesth agents (e.g. morphine), SSRIs, organophosphate insecticides. Increased susceptibility to the effects of suxamethonium-exacerbated hyperkalaemia w/ digitalis-like drugs.
Tác dụng
Description: Suxamethonium Cl is an ultrashort-acting depolarising type skeletal muscle relaxant. It blocks the neuromuscular junction by binding to the cholinergic receptors and depolarising it.
Onset: 0.5-1 min (IV); approx 2-3 min (IM).
Duration: 4-6 min (IV); 10-30 min (IM).
Distribution: Crosses the placenta (small amounts).
Metabolism: Rapidly hydrolysed by plasma cholinesterase.
Excretion: Via urine, approx 10% as unchanged drug.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Succinylcholine, CID=5314, (accessed on Jan. 23, 2020)

Bảo quản
Store between 2-8°C.
Phân loại MIMS
Thuốc ức chế thần kinh cơ
Tài liệu tham khảo
Anon. Succinylcholine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 29/10/2015.

Buckingham R (ed). Suxamethonium Chloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 29/10/2015.

Joint Formulary Committee. Suxamethonium Chloride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 29/10/2015.

McEvoy GK, Snow EK, Miller J et al (eds). Succinylcholine Chloride. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). Accessed 29/10/2015.

Quelicin Succinylcholine Chloride Injection, Solution (Hospira, Inc.). DailyMed. Source: U.S. National Library of Medicine. Accessed 29/10/2015.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Suxamethonium từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Suxamethonium Rotexmedica
  • Suxamethonium Shanghai
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in